後發注射劑:市場預估.市場機會(∼2014年) 是由出版商Espicom Business Intelligence在2009年12月所出版的。
這份英文市場調查報告書包含Pages: 318 價格從美金2265起跳。
報告書内容包括:後發注射劑市場相關調査分析、癌症、CNS、心血管疾病、抗感染症、糖尿病等相關55種主要治療法的分析、提供市場相關主要的企業19家的評價、到2014年的産品預測、特許資訊、市場背景、主要的訴訟問題的分析彙整。概要内容如下:
摘要
概要
- 主要的後發醫藥品市場
- 注射劑
- 後發生物製劑
- 單細胞繁殖抗體
- 主要的治療領域
- 主要企業和競爭
癌症的注射劑
- 荷爾蒙療法
- Faslodex
- Zoladex
- Lupron Depot
- Eligard
- 化學療法
- Taxotere
- Abraxane
- Camptosar
- Eloxatin
- Gemzar
- Alimta
- Velcade
- ソOctreotideLAR療法
- 支持療法
- Zometa/Aclasta/Reclast
- Kytril
- G-CSF
- Neupogen
- Neulasta
- Neutrogin/Granocyte
- Leukine
- 紅血球生成素
- Epogen/Eprex
- Aranesp
- NeoRecormon/Epogin
- 單細胞繁殖抗體
抗感染症注射劑
- Merrem
- Zosyn
- Primaxin
- Levaquin
- Cancidas
- Vfend
- Tygacil
- 干擾素α
CNS注射劑
- 多發性硬化症
- 干擾素β
- Avonex
- Rebif
- Betaferon/Betsaseron
- 綜合失調症
- Abilify
- Risperdal Consta
- Zyprexa
- 其他
心血管疾病用注射劑
- Lovenox
- Arixtra
- Integrilin
- Angiomax
- Cardene IV
内分泌疾病
- 重組胰島素・似胰島素製劑
- Humulin
- Humalog
- Lantus
- Levemir
- NovoRapid/NovoLog
- NovoMix/NovoLog Mix
- 基因重組生長荷爾蒙
- Genotropin
- Humatrope
- Norditropin
- Nutropin
- Saizen/Serostim
發炎症疾病
企業個人檔案
附錄Ⅰ：FDA ANDA(醫藥品簡略許可申請) 許可藥
附錄Ⅱ：英國的許可後發注射劑
來源
Abstract
This market leading strategic analysis from Espicom provides the market
context for injectable generic drugs, individual analysis of 55 leading
therapies and evaluation of 19 companies active in the sector. Key therapy
sectors include cancer, CNS, cardiovascular, anti-infectives, diabetes, growth
disorders and inflammatory conditions.
For more than half of the injectable generics approved in recent years, just
one or two manufacturers have received ANDA approvals and 86% of molecules
have fewer than five generic competitors
The generic industry is known for producing ' affordable medicines' . Cost has
been an important factor in their development, particularly for oral drugs
that are relatively cheap to produce and can be introduced to the market at a
fraction of the price of the original drugs. As the generic industry matures
however, companies are increasingly looking towards alternative drug delivery
technologies as a route to a competitive edge in a crowded market.
A changing corporate landscape
The continuing importance of the injectable generic sector is evidenced by the
ongoing developments in the corporate landscape. Pfizer' s agreements with
Aurobindo and Claris Lifesciences have been strengthened and Novartis'
acquisition of Ebewe has improved Sandoz' s access to injectable products.
Akorn Strides and Fresenius Kabi are new names to the top flight, with the
latters acquisition of Dabur and APP putting it in a strong position in the US.
A biosimilar future
Generic manufacturers are beginning to look towards a biosimilar market for
future growth. While several biosimilars have now been approved in the EU, a
viable regulatory process has yet to be approved in the US. A biosimilar
regulation is now more or less agreed as part of President Obama' s general
health reform bill, but it remains to be seen whether or not this will be
passed. Despite the hurdles, for those companies with the capability to
produce biologicals, and the money to invest in their development, there is
enormous potential in this high-value market.
This report provides...
- Individual analysis of 55 leading therapies
- Product forecasts by value 2009/2014
- Comprehensive patent information by product and expiry date
- The market context for injectable drugs
- Evaluation of 19 companies competing in the sector
- Analysis of significant litigation
Key therapy sectors covered
- Cancer
- CNS
- Cardiovascular
- Anti-Infectives
- Diabetes
- Growth Disorders
- Anti-inflammatory
Table of Contents
Foreword
Executive Summary
Overview
- Leading Generic Markets
- Injectables
- Biosimilars
- Monoclonal Antibodies
- Major Therapeutic Areas
- Leading Companies and Competition
Cancer Injectables
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Prostate Cancer
- FDA Approved Generics
- Hormonal Therapies
- Faslodex (fulvestrant)
- Patents
- Market Outlook
- Zoladex (goserelin)
- Patents
- Generic Company Activity
- Market Outlook
- Lupron Depot (leuprorelin)
- Patents
- Generic Company Activity
- Market Outlook
- Eligard (leuprolide)
- Patents
- Chemotherapy
- Taxotere (docetaxel)
- NICE Guidance
- Patents
- Generic Company Activity
- Formulation
- API
- Compulsory Licensing
- Market Outlook
- Abraxane (paclitaxel protein-bound particles for injectable suspension;
albumin-bound)
- Patents
- Litigation
- Generic Company Activity
- Market Outlook
- Camptosar (irinotecan)
- NICE Guidance
- Patents
- Generic Company Activity
- Market Outlook
- Eloxatin (oxaliplatin)
- NICE Guidance
- Patents
- Generic Company Activity
- Teva
- Hospira
- Sun Pharma
- Fresenius Kabi Oncology
- Ebewe (Sandoz)
- Pliva
- Market Outlook
- Gemzar (gemcitabine)
- Patents
- Generic Company Activity
- Market Outlook
- Alimta (pemetrexed)
- NICE Guidance
- Patents
- Generic Company Activity
- Market Outlook
- Velcade (bortezomib)
- Patents
- Generic Company Activity
- Market Outlook
- Somatostatin Analogue
- Sandostatin (octreotide acetate)
- Patents
- Generic Company Activity
- Market Outlook
- Supportive Therapies
- Zometa/Aclasta/Reclast (zoledronic acid)
- FDA Alert on Bisphosphonates
- Patents
- Generic Company Activity
- Market Outlook
- Kytril (granisetron)
- Patents
- Generic Company Activity
- Market Outlook
- G-CSF
- Biosimilar Activity
- Teva, ratiopharm and CT Arzneimittel receive EU approval
- Teva submits BLA for XM02 for CT-induced neutropenia
- Sandoz gains EC filgrastim approval
- Hospira acquires rights to biosimilar filgrastim
- Cangene signs deal for Maxygen' s MAXY-G34 in ARS
- Merck acquires follow-on biologics platform from Insmed
- Apotex
- Abraxis/Biocon
- EMEA Guidelines for Recombinant Granulocyte-Colony Stimulating Factor
- Neupogen (filgrastim)
- Patents
- Market Outlook
- Neulasta (pegfilgrastim)
- Market Outlook
- Neutrogin/Granocyte (lenograstim)
- Market Outlook
- Leukine (sargramostim)
- Patents
- Erythropoietin
- Biosimilar Activity
- Positive opinions from the EMEA for two more biosimilars
- First biosimilar approvals for EPO in the EU
- EMEA recommendation of new warning for EPO in cancer patients
- Epogen/Eprex (epoetin alpha)
- Patents
- Market Outlook
- Aranesp (darbepoetin alpha)
- Patents
- Biosimilar Activity
- Market Outlook
- NeoRecormon/Epogin (epoetin beta)
- Market Outlook
- Monoclonal Antibodies
- Rituxan/Mab Thera (rituximab)
- Rituximab potential in Type I diabetes
- Biosimilar Activity
- Market Outlook
Injectable Anti-infectives
- FDA Approved Generics
- Merrem (meropenem)
- Patents
- Generic Company Activity
- Market Outlook
- Zosyn (piperacillin+tazobactam)
- Patents
- Generic Company Activity
- Market Outlook
- Primaxin (imipenem+cilastatin sodium)
- Patents
- Generic Company Activity
- Market Outlook
- Levaquin (levofloxacin)
- Patents
- Generic Company Activity
- Market Outlook
- Cancidas (caspofungin acetate)
- Patents
- Generic Company Activity
- Market Outlook
- Vfend (voriconazole)
- Patents
- Generic Company Activity
- Market Outlook
- Tygacil (tygacycline)
- Patents
- Generic Company Activity
- Market Outlook
- Cubicin (daptomycin)
- Patents
- Generic Company Activity
- Interferon alpha
- Biosimilar Activity
- EMEA issues draft guidelines for biosimilar interferon alpha
- Intron A (interferon alpha-2b)
- Market Outlook
- PegIntron (peginterferon alpha-2b)
- Market Outlook
- Pegasys (pegylated-40K interferon alpha-2a)
- Market Outlook
CNS Injectables
- FDA Approved Generics
- Multiple Sclerosis
- Copaxone (glatiramer)
- Patents
- Generic Company Activity
- Sandoz and Momenta
- Mylan and Natco Pharma
- Market Outlook
- Interferon beta
- Biopartners withdraws interferon beta application
- Avonex (interferon beta-1a)
- Patents
- Market Outlook
- Rebif (interferon beta-1a)
- Market Outlook
- Betaferon/Betsaseron (interferon beta-1b)
- Patents
- Market Outlook
- Schizophrenia
- Abilify (aripiprazole)
- Patents
- Generic Company Activity
- Market Outlook
- Risperdal Consta (risperidone)
- Patents
- Generic Company Activity
- Market Outlook
- Zyprexa (olanzapine)
- Patents
- Generic Company Activity
- Market Outlook
- Other
- Precedex (dexmedetomidine)
- Patents
- Generic Company Activity
Cardiovascular Injectables
- EMEA Guideline on Non-Clinical and Clinical Development of Similar
Biological Medicinal Products
- Containing Low-Molecular-Weight-Heparins
- FDA Approved Generics
- Lovenox (enoxaparin)
- Patents
- Generic Company Activity
- Market Outlook
- Arixtra (fondaparinux)
- Patents & Exclusivity
- Generic Company Activity
- Market Outlook
- Integrilin (eptifibatide)
- Patents
- Generic Company Activity
- Market Outlook
- Angiomax (bivalrudin)
- Patents
- Generic Company Activity
- Market Outlook
- Cardene IV (nicardipine)
- Patents
- Generic Company Activity
Endocrine Disorders
- Recombinant Insulin & Insulin Analogues
- Biosimilar Activity
- Biocon
- Bioton
- EMEA Guidelines for Recombinant Human Insulin
- Humulin (insulin human [rDNA origin])
- Market Outlook
- Humalog (insulin lispro)
- Patents
- Market Outlook
- Lantus (insulin glargine)
- Safety Issues
- Patents
- Market Outlook
- Levemir (insulin detemir)
- Patents
- Market Outlook
- NovoRapid/NovoLog (insulin aspart)
- Patents
- Market Outlook
- NovoMix/NovoLog Mix
- Patents
- Market Outlook
- Recombinant Human Growth Hormone
- Biosimilar Activity
- Sandoz
- BioPartners
- Cangene
- Teva
- EMEA Guidelines for Somatropin
- Genotropin
- Patents
- Market Outlook
- Humatrope
- Market Outlook
- Norditropin
- Patents
- Market Outlook
- Nutropin
- Patents
- Market Outlook
- Saizen/Serostim
- Market Outlook
Inflammatory Conditions.
- Enbrel (etanercept)
- Patents
- Biosimilar Activity
- Market Outlook
- Remicade (infliximab)
- Market Outlook
Company Profiles
- Akorn
- Products
- Financials
- Agreements
- Akorn enters agreement for injectable products with Bioniche
- Akorn signs premix product supply agreement with Fresenius
- Akorn enters ANDA development and supply agreement with Hyaluron
- Amphastar Pharmaceuticals
- Injectable Products
- Proposed generic enoxaparin
- Apotex
- Injectable Products
- Financials
- Agreements
- Apotex to develop biosimilar G-CSF with IBP
- Orchid Chemicals & Pharmaceuticals
- BioGeneriX
- Litigation
- Sanofi-aventis sues Apotex over docetaxel
- Baxter
- Generic Injectable Products
- Financials
- Bedford Laboratories
- Products
- Financials
- Agreements
- Novo Nordisk
- Claris Lifesciences
- Products
- Marketing agreement with Pfizer
- Fresenius Kabi
- Products
- Financials
- Acquisitions
- APP Acquisition
- Dabur acquisition
- GeneraMedix
- Products
- Agreements
- Watson and GeneraMedix reach sodium ferric gluconate licence agreement
- GeneraMedix to sell improved epoprostenol formulation to Actelion
- HollisterStier enters agreement with GeneraMedix
- Akorn signs commercial manufacturing supply agreement with GeneraMedix
- Hikma Pharmaceuticals
- Injectable Products
- Financials
- Acquisitions & Agreements
- Acquisition of Egypt' s Alkan Pharma
- Acquisition of Thymoorgan
- Acquisition of Ribosepharm
- Hikma and Hospira enter European marketing agreements
- Hospira
- Products
- Financials
- Acquisitions & Agreements
- Hospira and Celltrion enter biosimilars agreement
- Hospira gains filgrastim rights and manufacturing facility from Pliva
- Mayne Pharma acquisition
- Hikma Pharmaceuticals agreement
- Orchid Chemicals & Pharmaceuticals
- Products
- Financials
- Agreements, Acquisitions & Joint Ventures
- Strategic alliance with Ranbaxy
- Actavis agreement
- Apotex agreement
- Bexel Pharmaceuticals Inc.
- Biotechnological Chemical Development Ltd.
- Mano Pharmaceuticals & Sali Healthcare
- NCPC Orchid Pharmaceuticals Ltd.
- Paddock Laboratories
- PharmaForce
- Sagent Pharmaceuticals
- Products
- Agreements
- Agreement with Astral
- Agreement with Strides Arcolab
- Co-promotion agreement with Anesiva
- Sandoz
- Products
- Biosimilars
- Financials
- Major Developments
- Teva files amended complaint against Momenta/Sandoz
- Sandoz completes acquisition of Ebewe Pharma injectables business
- Sandoz receives regulatory guidance on enoxaparin ANDA
- Collaboration with Momenta Pharmaceuticals
- Strides Arcolab
- Sun Pharma
- Products
- Financials
- Acquisitions
- Able Laboratories acquisition
- Caraco equity stake
- Teva Pharmaceutical Industries
- Products
- Antares/Teva file sNDA for needlefree injector for HGH product
- Financials
- Major Developments
- Teva files amended complaint against Momenta/Sandoz
- CHMP adopts positive opinion on Taxotere and Temodal generics
- FDA accepts Mylan ANDA for glatiramer
- Sicor acquisition
- Wockhardt
- Injectable Products
- Financials
- Acquisitions
- Morton Grove acquisition
- Wockhardt acquires France' s Negma Laboratories
Appendix I: FDA ANDA Approvals
Appendix II: UK Injectable Generic Approvals
SOURCES
List of Tables
- US Patent Expiry for Major Injectable Drugs
- Biosimilars Approved in the EU
- Leading Monoclonal Antibodies
- Injectables with Eight or More Generic Competitors in the US Market
- Cancer in the US, 2010 Estimates
- FDA Approved Generic Cancer Injectables, 2004-2009
- Faslodex Sales 2004-2008 (US$ Million)
- Faslodex US Patent
- Zoladex Sales, 2004-2008 (US$ Million)
- Zoladex US Patents
- Lupron Depot/Leuplin Sales, 2004-2008 (US$ Million)
- Lupron Depot US Patents
- FDA ANDA Approvals for Leuprolide
- Eligard US Patents
- Taxotere Sales, 2004-2008 (EUR & US$ Million)
- Taxotere US Patents
- Abraxane Sales, 2005-2008 (US$ Million)
- Abraxane US Patents
- FDA ANDA Approvals for Paclitaxel
- Camptosar Sales, 2004-2008 (US$ Million)
- Camptosar US Patents
- FDA ANDA Approvals for Irinotecan
- Eloxatin Sales, 2004-2008 (EUR & US$ Million)
- Eloxatin US Patents
- Gemzar Sales, 2004-2008 (US$ Million)
- Gemzar US Patents
- FDA ANDA Approval for Gemcitabine
- Tentative ANDA Approvals for Gemcitabine
- Alimta Sales, 2004-2008 (US$ Million)
- Alimta US Patents
- Velcade Sales, 2007-2008 (US$ Million)
- Velcade US Patents
- Sandostatin Sales, 2004-2008 (US$ Million)
- Sandostatin US Patents
- FDA ANDA Approvals for Octreotide Acetate
- Sandostatin Sales, 2004A-2014E (US$ Million)
- Zometa Sales, 2004-2008 (US$ Million)
- Zometa US Patents
- Kytril Sales, 2003-2007 (SFr & US$ Million)
- Kytril US Patents
- FDA ANDA Approvals for Granisetron Injection
- Neupogen Sales, 2004-2008 (US$ Million
- Neulasta Sales, 2004-2008 (US$ Million)
- Neutrogin/Granocyte Sales, 2004-2008 (¥ Billion & US$ Million)
- Epogen/Eprex Sales, 2004-2008 (US$ Million)
- Amgen' s Erythropoietin US Patents
- Aranesp Sales, 2004-2008 (US$ Million)
- NeoRecormon/Epogin Sales, 2004-2008 (CHF & US$ Million)
- FDA Approved Generic Anti-infective Injectables, 2004-2009
- Merrem Sales, 2004-2008 (US$ Million)
- Meropen Sales, 2004-2008 (¥ Billion & US$ Million)
- Merrem US Patent
- Zosyn Sales, 2004-2008 (US$ Million)
- Primaxin Sales, 2004-2008 (US$ Million)
- Levaquin/Floxin Sales, 2004-2008 US$ Million)
- Cravit Sales, 2004-2008 (¥ Million & US$ Million)
- Levaquin US Patent
- Tentative ANDA Approvals for Levofloxacin Injection
- Cancidas Sales, 2004-2008 (US$ Million)
- Cancidas US Patents
- Vfend Sales, 2004-2008 (US$ Million)
- Vfend US Patents
- Tygacil Sales 2005-2008 (US$ Million)
- Tygacil US Patents
- Cubicin Sales 2004-2008 (US$ Million)
- Cubicin US Patents
- Intron A Sales, 2004-2008 (US$ Million)
- PegIntron Sales, 2004-2008 (US$ Million)
- Pegasys Sales, 2003-2008 (SFr & US$ Million)
- FDA Approved Generic CNS Injectables, 2004-2009
- FDA ANDA Approvals for Mitoxantrone
- Copaxone Sales, 2004-2008 (EUR & US$ Million)
- Copaxone US Patents
- Avonex Sales, 2004-2008 (US$ Million)
- Rebif Sales, 2004-2008 (EUR & US$ Million)
- Betaferon/Betaseron Sales, 2004-2008 (EUR & US$ Million)
- Abilify Sales, 2004-2008 (US$ Million)
- Abilify Injection US Patents
- Risperdal Consta Sales, 2006-2008 (US$ Million)
- Risperdal Consta US Patents
- Zyprexa Sales, 2004-2008 (US$ Million)
- Zyprexa Injection US Patent
- Precedex US Patents
- FDA Approved Generic Cardiovascular Injectables, 2004-2009
- Lovenox/Clexane Sales, 2004-2008 (EUR & US$ Million)
- Lovenox US Patents
- Arixtra Sales, 2004-2008 (£ & US$ Million)
- Integrilin Sales, 2004-2008 (US$ Million)
- Integrilin US Patents
- Angiomax Sales, 2004-2008 (US$ Million)
- Angiomax US Patents
- Cardene IV US Patent
- Humulin Sales, 2004-2008 (US$ Million)
- Humalog Sales, 2004-2008 (US$ Million)
- Humalog US Patents
- Lantus Sales, 2004-2008 (EUR & US$ Million)
- Lantus US Patents
- Levemir Sales, 2005-2008 (DKr & US$ million)
- Levemir US Patents
- NovoRapid/NovoLog Sales, 2005-2008 (DKr & US$ million)
- NovoLog US Patents
- NovoLog Mix US Patents
- Genotropin Sales, 2004-2008 (US$ Million)
- Genotropin US Patents
- Humatrope Sales, 2003-2007 (US$ Million)
- Novo Nordisk Growth Hormone Therapy Sales, 2004-2008 (DKr & US$ Million)
- Norditropin US Patents
- Nutropin/Protropin Sales, 2004-2008 (SFr & US$ Million)
- Nutropin US Patent
- Saizen & Serostim Sales, 2004-2008 (EUR & US$ Million)
- Enbrel Sales, 2004-2008 (US$ Million)
- Enbrel US Patents
- Remicade Sales, 2004-2008 (US$ Million)
- Akorn ANDA Approvals for Injectables, 2008-2009
- Akorn-Strides ANDA Approvals, 2007-2009
- Akorn Financial Results, 2004-2008 (US$ Million)
- Amphastar ANDA Approval
- International Medication Systems ANDA Approvals, 2002-2005
- Apotex ANDA Approvals for Injectables, 2002-2009
- Cangene Financial Results, 2004-2008 (C$ Million)
- Baxter ANDA Approvals for Injectables, 2002-2008
- Baxter Financial Results, 2004-2008 (US$ Million)
- Bedford Laboratories ANDA Approvals, 2002-2009
- Bedford Laboratories Sales, 2005-2007 (EUR & US$ Million)
- Claris Lifesciences ANDA Approvals
- APP ANDA Approvals, 2002-2009
- Fresenius Kabi Oncology ANDA Approvals, 2006-2009
- Fresenius Kabi Financial Results, 2005-2008 (US$ Million)
- APP Financial Results, 2004-2007 (US$ Million)
- GeneraMedix ANDA Approvals, 2007-2009
- Hikma ANDA Approvals for Injectables, 2002-2009
- Hikma Financial Results, 2004-2008 (US$ Million)
- Hospira ANDA Approvals, 2004-2009
- Abbott ANDA Approvals for Injectables, 2002-2004
- Hospira Tentative ANDA Approval
- Hospira Financial Results by Region, 2006-2008 (US$ Million)
- Orchid Healthcare ANDA Approvals for Injectables, 2005-2009
- Orchid Financial Results, 2005-2009
- Paddock Laboratories ANDA Approvals for Injectables, 2003-2009
- PharmaForce ANDA Approvals for Injectables, 2002-2009
- Sagent Strides ANDA Approval
- Approved ANDAs Acquired From Spectrum Pharmaceuticals
- Sandoz ANDA Approvals for Injectables, 2005-2009
- Ebewe Pharma ANDA Approvals for Injectables, 2007-2009
- Sabex ANDA Approvals, 2003-2005
- Eon Labs ANDA Approval for Injectable, 2005
- Biochemie ANDA Approval for Injectable, 2002
- Sandoz financial results, 2004-2008 (US$ Million)
- Akorn-Strides ANDA Approvals
- Sagent-Strides ANDA Approvals
- Strides Financial Results, 2005-2008
- Sun Pharma ANDA Approvals for Injectables
- Sun Pharma Tentative ANDA Approval for Injectable
- Sun Pharma: Financial Results, 2005-2009
- Teva Parenteral ANDA Approvals, 2002-2009
- Teva Pharmaceuticals ANDA Approvals for Injectables, 2006
- Pliva ANDA Approvals for Injectables, 2004-2008
- Pharmachemie ANDA Approvals for Injectables, 2004-2007
- Teva Financial Results, 2004-2008 (US$ millions)
- Wockhardt ANDA Approvals for Injectables
- Wockhardt Financial Results, 2004-2008
- FDA ANDA Approvals for Injectable Drugs, 2007-2009
- UK MHRA Injectable Generic Approvals, 2007-2009
List of Figures
- Generic Pharmaceutical Expenditure, 2009 (US$ Billions)
- Generic Pharmaceutical Expenditure per capita, 2009 (US$)
- Generic Pharmaceutical Expenditure as % of Total, 2009
- FDA ANDA Approvals by Therapeutic Area, 2004-2009
- FDA ANDA Approvals by Therapeutic Area, 2004-2009 (%)
- FDA ANDA Approvals by Company 2004-2009
- FDA ANDA Approvals by Company 2008-2009
- Competition for Generic Injectables
- Regional Cancer Deaths as % of Total Deaths, 2008
- Global Cancer Deaths by Region (%)
- Faslodex Sales, 2004A-2014E (US$ Million
- Zoladex Sales, 2004A-2014E (US$ Million)
- Lupron Sales, 2004A-2014E (US$ Million)
- Taxotere Sales, 2004A-2014E (US$ Million)
- Abraxane Sales, 2005A-2014E (US$ Million)
- Camptosar Sales, 2004A-2014E (US$ Million)
- Eloxatin Sales, 2004A-2014E (US$ Million)
- Gemzar Sales, 2004A-2014E (US$ Million)
- Alimta Sales, 2004A-2014E (US$ Million)
- J&J' s Sales of Velcade, 2007A-2014E (US$ Million)
- Zometa/Aclasta/Reclast Sales, 2004A-2014E (US$ Million)
- Kytril Sales, 2004A-2014E (US$ Million)
- Neupogen Sales, 2004A-2014E (US$ Million)
- Neulasta Sales, 2004A-2014E (US$ Million)
- Neutrogin/Granocyte Sales, 2004A-2014E (US$ Million)
- Epogen/Eprex Sales, 2004A-2014E (US$ Million)
- Aranesp Sales, 2004A-2014E (US$ Million)
- NeoRecormon/Epogin Sales, 2004A-2014E (US$ Million)
- Rituxan/Mab Thera Sales, 2004A-2014E
- Merrem/Meropen Sales, 2004A-2014E (US$ Million)
- Zosyn/Tazocin Sales, 2004A-2014E (US$ Million)
- Primaxin Sales, 2004A-2014E (US$ Million)
- Levaquin/Cravit Sales, 2004A-2014E (US$ Million)
- Cancidas Sales, 2004A-2014E (US$ Million)
- Vfend Sales, 2004A-2014E (US$ Million)
- Tygacil Sales, 2005A-2014E (US$ Million)
- Intron-A Sales, 2004A-2014E (US$ Million)
- PegIntron Sales, 2004A-2014E (US$ Million)
- Pegasys Sales, 2004A-2014E (US$ Million)
- Copaxone Sales, 2004A-2014E (US$ Million)
- Avonex Sales, 2004A-2014E (US$ Million)
- Rebif Sales, 2004A-2014E (US$ Million)
- Betaferon/Betaseron Sales, 2004A-2014E (US$ Million)
- Abilify Sales (all formulations), 2004A-2014E (US$ Million)
- Risperdal Consta Sales, 2006A-2014E (US$ Million)
- Zyprexa Sales (all formulations), 2004A-2014E (US$ Million)
- Lovenox Sales, 2004A-2014E (US$ Million)
- Arixtra Sales, 2004A-2014E (US$ Million)
- Integrilin Sales, 2004A-2014E (US$ Million)
- Angiomax Sales, 2004A-2014E (US$ Million)
- Humulin Sales, 2004A-2014E (US$ Million)
- Humalog Sales, 2004A-2014E (US$ Million)
- Lantus Sales, 2004A-2014E (US$ Million)
- Levemir Sales, 2005-2014E (US$ Million)
- NovoRapid/NovoLog Sales, 2005-2014E (US$ Million)
- NovoMix/NovoLog Sales 2005-2014E (US$ Million)
- Genotropin Sales, 2004A-2014E (US$ Million)
- Humatrope Sales, 2004A-2014E (US$ Million)
- Novo Nordisk Growth Hormone Therapy Sales, 2004A-2014E (US$ Million)
- Nutropin/Protropin Sales, 2004A-2014E (US$ Million)
- Saizen/Serostim Sales, 2004A-2014E (US$ Million)
- Amgen Enbrel Sales, 2004A-2014E (US$ Million)
- Wyeth Enbrel Sales, 2004A-2014E (US$ Million)
- J&J Remicade Sales, 2004A-2014E (US$ Million)
- Schering-Plough Remicade Sales, 2004A-2014E (US$ Million)
|
